A single immunization with CAF08 provides newborns with Th1-mediated protection against Respiratory Syncytial Virus infection

Abstract Respiratory Syncytial Virus (RSV) is a leading cause of morbidity and mortality in children, due part to their distinct immune system, characterized by impaired induction T-helper 1 (Th1)□immunity. Here we describe cationic adjuvant formulation (CAF)-08, liposomal vaccine tailored induce Th1 immunity early life via synergistic engagement Toll-like Receptor 7/8 the C-type lectin receptor Mincle. Quantitative phosphoproteomics applied human dendritic cells revealed key role for Protein Kinase C-d enhanced cytokine production neonatal identified signaling events resulting antigen cross-presentation. In vivo, single immunization at birth with CAF08-adjuvanted RSV pre-fusion protected newborn mice from infection through antigen-specific CD8+ cells. Overall, novel pediatric characterize its mechanism action providing promising avenue development vaccines against other intracellular pathogens.